In particular, at the single gene level, low levels of expression of APOA5, PON1, PON3 and CD14 associated with better prognosis, and in contrast, low expression of RAP1B was associated with worse prognosis, supporting our proteomics data showing a significant decrease in CD81sEV in stage III–IV melanoma patients (Figure S5A,B and Figure 4A). Here, APOA5 is linked to melanoma.